X

Drug Profile

Lanreotide injection - Cipla

Latest Information Update: 22 Dec 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cipla
Class Antineoplastics; Cyclic peptides; Eye disorder therapies; Pancreatic hormones; Pituitary hormone release inhibiting hormones; Urologics; Vascular disorder therapies
Mechanism of Action Growth hormone-releasing hormone inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Registered Acromegaly; Neuroendocrine tumours

Most Recent Events

19 Dec 2021 Registered for Acromegaly in USA (SC)
19 Dec 2021 Registered for Neuroendocrine tumours in USA (SC)
19 Dec 2021 The US FDA approves Lanreotide injection for Acromegaly and Neuroendocrine tumours in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com